<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35624818</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3921</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Antioxidants (Basel, Switzerland)</Title><ISOAbbreviation>Antioxidants (Basel)</ISOAbbreviation></Journal><ArticleTitle>Antioxidant Genetic Profile Modifies Probability of Developing Neurological Sequelae in Long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antiox11050954</ELocationID><Abstract><AbstractText>Understanding the sequelae of COVID-19 is of utmost importance. Neuroinflammation and disturbed redox homeostasis are suggested as prevailing underlying mechanisms in neurological sequelae propagation in long-COVID. We aimed to investigate whether variations in antioxidant genetic profile might be associated with neurological sequelae in long-COVID. Neurological examination and antioxidant genetic profile (SOD2, GPXs and GSTs) determination, as well as, genotype analysis of Nrf2 and ACE2, were conducted on 167 COVID-19 patients. Polymorphisms were determined by the appropriate PCR methods. Only polymorphisms in GSTP1AB and GSTO1 were independently associated with long-COVID manifestations. Indeed, individuals carrying <i>GSTP1 Val</i> or <i>GSTO1 Asp</i> allele exhibited lower odds of long-COVID myalgia development, both independently and in combination. Furthermore, the combined presence of <i>GSTP1 Ile</i> and <i>GSTO1 Ala</i> alleles exhibited cumulative risk regarding long-COVID myalgia in carriers of the combined <i>GPX1 LeuLeu/GPX3 CC</i> genotype. Moreover, individuals carrying combined <i>GSTM1-null/GPX1LeuLeu</i> genotype were more prone to developing long-COVID "brain fog", while this probability further enlarged if the <i>Nrf2 A</i> allele was also present. The fact that certain genetic variants of antioxidant enzymes, independently or in combination, affect the probability of long-COVID manifestations, further emphasizes the involvement of genetic susceptibility when SARS-CoV-2 infection is initiated in the host cells, and also months after.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ercegovac</LastName><ForeName>Marko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Neurology, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asanin</LastName><ForeName>Milika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Cardiology, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savic-Radojevic</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2026-4180</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranin</LastName><ForeName>Jovan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matic</LastName><ForeName>Marija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djukic</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coric</LastName><ForeName>Vesna</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0227-821X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jerotic</LastName><ForeName>Djurdja</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todorovic</LastName><ForeName>Nevena</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milosevic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4331-3328</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevanovic</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simic</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8683-5129</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences, Serbian Academy of Sciences and Arts, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukumiric</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Statistics and Informatics, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pljesa-Ercegovac</LastName><ForeName>Marija</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8969-0594</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>7546803, entitled AntioxIdentification</GrantID><Agency>Science Fund of the Republic of Serbia, Special Research Program on COVID-19</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antioxidants (Basel)</MedlineTA><NlmUniqueID>101668981</NlmUniqueID><ISSNLinking>2076-3921</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidant enzymes</Keyword><Keyword MajorTopicYN="N">glutathione transferases</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">neurological manifestations</Keyword><Keyword MajorTopicYN="N">polymorphisms</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35624818</ArticleId><ArticleId IdType="pmc">PMC9138155</ArticleId><ArticleId IdType="doi">10.3390/antiox11050954</ArticleId><ArticleId IdType="pii">antiox11050954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stefanou M.-I., Palaiodimou L., Bakola E., Smyrnis N., Papadopoulou M., Paraskevas G.P., Rizos E., Boutati E., Grigoriadis N., Krogias C. Neurological manifestations of long-COVID syndrome: A narrative review. Ther. Adv. Chronic Dis. 2022;13:20406223221076890. doi: 10.1177/20406223221076890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson C.J., Sarangi A., Bangash F. Neurological sequelae of COVID-19: A review. Egypt. J. Neurol. Psychiatry Neurosurg. 2021;57:1&#x2013;8. doi: 10.1186/s41983-021-00379-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41983-021-00379-0</ArticleId><ArticleId IdType="pmc">PMC8424148</ArticleId><ArticleId IdType="pubmed">34511868</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolen L.T., Mukerji S.S., Mejia N.I. Post-acute neurological consequences of COVID-19: An unequal burden. Nat. Med. 2022;28:20&#x2013;23. doi: 10.1038/s41591-021-01647-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01647-5</ArticleId><ArticleId IdType="pubmed">35039657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Taylor S. NICE guideline on long COVID. BMJ. 2020;371:m4938. doi: 10.1136/bmj.m4938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long COVID. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wang F., Shen Y., Zhang X., Cen Y., Wang B., Zhao S., Zhou Y., Hu B., Wang M. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw. Open. 2021;4:e2127403. doi: 10.1001/jamanetworkopen.2021.27403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.27403</ArticleId><ArticleId IdType="pmc">PMC8482055</ArticleId><ArticleId IdType="pubmed">34586367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Florencio L.L. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification. Int. J. Environ. Res. Public Health. 2021;18:2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-Term-Effects-of-Coronavirus.  [(accessed on 24 March 2022)].  Available online:  https://www.nhs.uk/conditions/coronavirus-covid-19.</Citation></Reference><Reference><Citation>Liguori C., Pierantozzi M., Spanetta M., Sarmati L., Cesta N., Iannetta M., Ora J., Mina G.G., Puxeddu E., Balbi O. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav. Immun. 2020;88:11&#x2013;16. doi: 10.1016/j.bbi.2020.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.037</ArticleId><ArticleId IdType="pmc">PMC7235586</ArticleId><ArticleId IdType="pubmed">32416289</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo D., Picone P. Potential neurological effects of severe COVID-19 infection. Neurosci. Res. 2020;158:1&#x2013;5. doi: 10.1016/j.neures.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7333632</ArticleId><ArticleId IdType="pubmed">32628969</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R.W., Brown R.L., Benjamin L., Nortley R., Wiethoff S., Bharucha T., Jayaseelan D.L., Kumar G., Raftopoulos R.E., Zambreanu L. The emerging spectrum of COVID-19 neurology: Clinical, radiological and laboratory findings. Brain. 2020;143:3104&#x2013;3120. doi: 10.1093/brain/awaa240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou S.H., Beghi E., Helbok R. GCS-NeuroCOVID Consortium and ENERGY Consortium: Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw. Open. 2021;4:e2112131. doi: 10.1001/jamanetworkopen.2021.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12131</ArticleId><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A.L.R., Hardwick M., Jeyanantham A., White L.M., Deb S., Burnside G., Joy H.M., Smith C.J., Pollak T.A., Nicholson T.R. Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: A UK-wide cross-sectional surveillance study. Brain Commun. 2021;3:fcab168. doi: 10.1093/braincomms/fcab168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab168</ArticleId><ArticleId IdType="pmc">PMC8364668</ArticleId><ArticleId IdType="pubmed">34409289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M. Deleterious outcomes in long-hauler COVID-19: The effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem. Neurosci. 2020;11:4017&#x2013;4020. doi: 10.1021/acschemneuro.0c00725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiani B., Covarrubias C., Desai A., Sekhon M., Jarrah R. A contemporary review of neurological sequelae of COVID-19. Front. Neurol. 2020;11:640. doi: 10.3389/fneur.2020.00640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00640</ArticleId><ArticleId IdType="pmc">PMC7324652</ArticleId><ArticleId IdType="pubmed">32655489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavassoly O., Safavi F., Tavassoly I. Seeding brain protein aggregation by SARS-CoV-2 as a possible long-term complication of COVID-19 infection. ACS Chem. Neurosci. 2020;11:3704&#x2013;3706. doi: 10.1021/acschemneuro.0c00676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00676</ArticleId><ArticleId IdType="pubmed">33147014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Tang N., Peluso M.J., Iyer N.S., Torres L., Donatelli J.L., Munter S.E., Nixon C.C., Rutishauser R.L., Rodriguez-Barraquer I. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. 2021;10:386. doi: 10.3390/cells10020386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes I.G., De Brito C.A., Dos Reis V.M.S., Sato M.N., Pereira N.Z. SARS-CoV-2 and other respiratory viruses: What does oxidative Stress have to do with it? Oxid. Med. Cell. Longev. 2020;2020:8844280. doi: 10.1155/2020/8844280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8844280</ArticleId><ArticleId IdType="pmc">PMC7757116</ArticleId><ArticleId IdType="pubmed">33381273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S. Oxidative Stress and Biomaterials. Elsevier; Amsterdam, The Netherlands: 2016. Oxidative stress, inflammation, and disease; pp. 35&#x2013;58.</Citation></Reference><Reference><Citation>Cheng Y., Sun F., Wang L., Gao M., Xie Y., Sun Y., Liu H., Yuan Y., Yi W., Huang Z. Virus-induced p38 MAPK activation facilitates viral infection. Theranostics. 2020;10:12223. doi: 10.7150/thno.50992.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.50992</ArticleId><ArticleId IdType="pmc">PMC7667676</ArticleId><ArticleId IdType="pubmed">33204339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosanovic T., Sagic D., Djukic V., Pljesa-Ercegovac M., Savic-Radojevic A., Bukumiric Z., Lalosevic M., Djordjevic M., Coric V., Simic T. Time Course of Redox Biomarkers in COVID-19 Pneumonia: Relation with Inflammatory, Multiorgan Impairment Biomarkers and CT Findings. Antioxidants. 2021;10:1126. doi: 10.3390/antiox10071126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071126</ArticleId><ArticleId IdType="pmc">PMC8301049</ArticleId><ArticleId IdType="pubmed">34356359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B., Dong D. Human cytosolic glutathione transferases: Structure, function, and drug discovery. Trends Pharmacol. Sci. 2012;33:656&#x2013;668. doi: 10.1016/j.tips.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2012.09.007</ArticleId><ArticleId IdType="pubmed">23121834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pljesa-Ercegovac M., Savic-Radojevic A., Matic M., Coric V., Djukic T., Radic T., Simic T. Glutathione transferases: Potential targets to overcome chemoresistance in solid tumors. Int. J. Mol. Sci. 2018;19:3785. doi: 10.3390/ijms19123785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19123785</ArticleId><ArticleId IdType="pmc">PMC6321424</ArticleId><ArticleId IdType="pubmed">30487385</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon D., Innes A., Oakley A.J., Dahlstrom J.E., Jensen L.M., Br&#xfc;stle A., Tummala P., Rooke M., Casarotto M.G., Baell J.B. GSTO1-1 plays a pro-inflammatory role in models of inflammation, colitis and obesity. Sci. Rep. 2017;7:17832. doi: 10.1038/s41598-017-17861-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17861-6</ArticleId><ArticleId IdType="pmc">PMC5736720</ArticleId><ArticleId IdType="pubmed">29259211</ArticleId></ArticleIdList></Reference><Reference><Citation>Djukic T., Stevanovic G., Coric V., Bukumiric Z., Pljesa-Ercegovac M., Matic M., Jerotic D., Todorovic N., Asanin M., Ercegovac M. GSTO1, GSTO2 and ACE2 Polymorphisms Modify Susceptibility to Developing COVID-19. J. Pers. Med. 2022;12:458. doi: 10.3390/jpm12030458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12030458</ArticleId><ArticleId IdType="pmc">PMC8955736</ArticleId><ArticleId IdType="pubmed">35330457</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvagno F., Vernone A., Pescarmona G.P. The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants. 2020;9:624. doi: 10.3390/antiox9070624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9070624</ArticleId><ArticleId IdType="pmc">PMC7402141</ArticleId><ArticleId IdType="pubmed">32708578</ArticleId></ArticleIdList></Reference><Reference><Citation>Coric V., Milosevic I., Djukic T., Bukumiric Z., Savic-Radojevic A., Matic M., Jerotic D., Todorovic N., Asanin M., Ercegovac M. GSTP1 and GSTM3 variant alleles affect susceptibility and severity of COVID-19. Front. Mol. Biosci. 2021;8:747493. doi: 10.3389/fmolb.2021.747493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.747493</ArticleId><ArticleId IdType="pmc">PMC8721193</ArticleId><ArticleId IdType="pubmed">34988113</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerotic D., Ranin J., Bukumiric Z., Djukic T., Coric V., Savic-Radojevic A., Todorovic N., Asanin M., Ercegovac M., Milosevic I. SOD2 rs4880 and GPX1 rs1050450 polymorphisms do not confer risk of COVID-19, but influence inflammation or coagulation parameters in Serbian cohort. Redox Rep. 2022;27:85&#x2013;91. doi: 10.1080/13510002.2022.2057707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13510002.2022.2057707</ArticleId><ArticleId IdType="pmc">PMC8979533</ArticleId><ArticleId IdType="pubmed">35361071</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo-Mart&#xed;nez W., Lozada-Mart&#xed;nez I., Escobar-Collazos A., Navarro-Coronado A., Moscote-Salazar L., Pacheco-Hern&#xe1;ndez A., Janjua T., Bosque-Varela P. Post-COVID 19 neurological syndrome: Implications for sequelae&#x2019;s treatment. J. Clin. Neurosci. 2021;88:219&#x2013;225. doi: 10.1016/j.jocn.2021.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8031003</ArticleId><ArticleId IdType="pubmed">33992187</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y., Wu J., Chen T., Li J., Zhang G., Wu D., Zhou Y., Zheng N., Cai A., Ning Q. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J. Clin. Investig. 2021;131:e147329. doi: 10.1172/JCI147329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI147329</ArticleId><ArticleId IdType="pmc">PMC8262559</ArticleId><ArticleId IdType="pubmed">33630760</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M., Bradner J., Bammler T.K., Eaton D.L., Zhang J., Ye Z., Wilson A.M., Montine T.J., Pan C., Zhang J. Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am. J. Pathol. 2009;175:54&#x2013;65. doi: 10.2353/ajpath.2009.081019.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2009.081019</ArticleId><ArticleId IdType="pmc">PMC2708794</ArticleId><ArticleId IdType="pubmed">19498008</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini S., Polimanti R., Squitti R., Mariani S., Migliore S., Vernieri F., Rossini P.M., Manfellotto D., Fuciarelli M. GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer&#x2019;s disease: Association hypothesis for an uncommon genetic variant. Neurosci. Lett. 2012;506:203&#x2013;207. doi: 10.1016/j.neulet.2011.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2011.11.005</ArticleId><ArticleId IdType="pubmed">22100662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercegovac M., Jovic N., Sokic D., Savic-Radojevic A., Coric V., Radic T., Nikolic D., Kecmanovic M., Matic M., Simic T. GSTA1, GSTM1, GSTP1 and GSTT1 polymorphisms in progressive myoclonus epilepsy: A Serbian case-control study. Seizure. 2015;32:30&#x2013;36. doi: 10.1016/j.seizure.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.seizure.2015.08.010</ArticleId><ArticleId IdType="pubmed">26552558</ArticleId></ArticleIdList></Reference><Reference><Citation>Eum K.-D., Seals R.M., Taylor K.M., Grespin M., Umbach D.M., Hu H., Sandler D.P., Kamel F., Weisskopf M.G. Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms. Amyotroph. Lateral Scler. Front. Degener. 2015;16:72&#x2013;79. doi: 10.3109/21678421.2014.964259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.964259</ArticleId><ArticleId IdType="pmc">PMC4467726</ArticleId><ArticleId IdType="pubmed">25293352</ArticleId></ArticleIdList></Reference><Reference><Citation>Allocati N., Masulli M., Di Ilio C., Federici L. Glutathione transferases: Substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018;7:8. doi: 10.1038/s41389-017-0025-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-017-0025-3</ArticleId><ArticleId IdType="pmc">PMC5833873</ArticleId><ArticleId IdType="pubmed">29362397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartoumpekis D.V., Wakabayashi N., Kensler T.W. Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism. Biochem. Soc. Trans. 2015;43:639&#x2013;644. doi: 10.1042/BST20150049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20150049</ArticleId><ArticleId IdType="pmc">PMC4613493</ArticleId><ArticleId IdType="pubmed">26551705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H.-Y., Marzec J., Kleeberger S.R. Functional polymorphisms in Nrf2: Implications for human disease. Free Radic. Biol. Med. 2015;88:362&#x2013;372. doi: 10.1016/j.freeradbiomed.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.06.012</ArticleId><ArticleId IdType="pmc">PMC6779133</ArticleId><ArticleId IdType="pubmed">26117318</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhang X., Ding Y., Zhou W., Tao L., Lu P., Wang Y., Hu R. Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming. Antioxid. Redox Signal. 2017;26:28&#x2013;43. doi: 10.1089/ars.2015.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6615</ArticleId><ArticleId IdType="pmc">PMC5198158</ArticleId><ArticleId IdType="pubmed">27308893</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S., Buttari B., Panieri E., Profumo E., Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020;25:5474. doi: 10.3390/molecules25225474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25225474</ArticleId><ArticleId IdType="pmc">PMC7700122</ArticleId><ArticleId IdType="pubmed">33238435</ArticleId></ArticleIdList></Reference><Reference><Citation>Michielsen H.J., De Vries J., Van Heck G.L. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J. Psychosom. Res. 2003;54:345&#x2013;352. doi: 10.1016/S0022-3999(02)00392-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(02)00392-6</ArticleId><ArticleId IdType="pubmed">12670612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross A.J., Medow M.S., Rowe P.C., Stewart J.M. What is brain fog? An evaluation of the symptom in postural tachycardia syndrome. Clin. Auton. Res. 2013;23:305&#x2013;311. doi: 10.1007/s10286-013-0212-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10286-013-0212-z</ArticleId><ArticleId IdType="pmc">PMC3896080</ArticleId><ArticleId IdType="pubmed">23999934</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama Y., Mitsuda Y., Tsuruta Y., Hamajima N., Niwa T. Polymorphism of Nrf2, an antioxidative gene, is associated with blood pressure and cardiovascular mortality in hemodialysis patients. Int. J. Med. Sci. 2014;11:726. doi: 10.7150/ijms.8590.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.8590</ArticleId><ArticleId IdType="pmc">PMC4045792</ArticleId><ArticleId IdType="pubmed">24904228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Pajares M., Benito C., Jim&#xe9;nez-Villegas J., Escoll M., Fern&#xe1;ndez-Gin&#xe9;s R., Yag&#xfc;e A.J.G., Lastra D., Manda G., Rojo A.I. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol. Sci. 2020;41:598&#x2013;610. doi: 10.1016/j.tips.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7359808</ArticleId><ArticleId IdType="pubmed">32711925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020;41:3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O&#x2019;Sullivan J.M. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt F.A., Havervall S., Adelmeijer J., Lundstr&#xf6;m A., Magnusson M., Mackman N., Thalin C., Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021;5:756&#x2013;759. doi: 10.1182/bloodadvances.2020003968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003968</ArticleId><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Yang Y., Fan X. Microvascular pericytes in brain-associated vascular disease. Biomed. Pharmacother. 2020;121:109633. doi: 10.1016/j.biopha.2019.109633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109633</ArticleId><ArticleId IdType="pubmed">31743876</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep. 2021;9:e14726. doi: 10.14814/phy2.14726.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14726</ArticleId><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. COVID and the brain: Researchers zero in on how damage occurs. Nature. 2021;595:484&#x2013;485. doi: 10.1038/d41586-021-01693-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01693-6</ArticleId><ArticleId IdType="pubmed">34234323</ArticleId></ArticleIdList></Reference><Reference><Citation>Checconi P., De Angelis M., Marcocci M.E., Fraternale A., Magnani M., Palamara A.T., Nencioni L. Redox-modulating agents in the treatment of viral infections. Int. J. Mol. Sci. 2020;21:4084. doi: 10.3390/ijms21114084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21114084</ArticleId><ArticleId IdType="pmc">PMC7312898</ArticleId><ArticleId IdType="pubmed">32521619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y., Bannai S., Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000;275:16023&#x2013;16029. doi: 10.1074/jbc.275.21.16023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.21.16023</ArticleId><ArticleId IdType="pubmed">10821856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Lavie C.J., Henry B.M., Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clin. Chem. Lab. Med. 2020;58:1415&#x2013;1422. doi: 10.1515/cclm-2020-0727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0727</ArticleId><ArticleId IdType="pubmed">32598305</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux C.A., Rolain J.-M., Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J. Microbiol. Immunol. Infect. 2020;53:425&#x2013;435. doi: 10.1016/j.jmii.2020.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.04.015</ArticleId><ArticleId IdType="pmc">PMC7201239</ArticleId><ArticleId IdType="pubmed">32414646</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniri A., Hosseini M.M., Akhavan-Niaki H. First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations. J. Biomol. Struct. Dyn. 2021;39:3576&#x2013;3593. doi: 10.1080/07391102.2020.1767690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1767690</ArticleId><ArticleId IdType="pmc">PMC7284145</ArticleId><ArticleId IdType="pubmed">32410502</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T., Shibata T., Takaya K., Shiraishi K., Kohno T., Kunitoh H., Tsuta K., Furuta K., Goto K., Hosoda F. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol. Cell. Biol. 2013;33:2402&#x2013;2412. doi: 10.1128/MCB.00065-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00065-13</ArticleId><ArticleId IdType="pmc">PMC3700104</ArticleId><ArticleId IdType="pubmed">23572560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini D., Galli F. The functional interactome of GSTP: A regulatory biomolecular network at the interface with the Nrf2 adaption response to oxidative stress. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2016;1019:29&#x2013;44. doi: 10.1016/j.jchromb.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2016.02.002</ArticleId><ArticleId IdType="pubmed">26922696</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;venin A.F., Zony C.L., Bahnson B.J., Colman R.F. GSTpi modulates JNK activity through a direct interaction with JNK substrate, ATF2. Protein Sci. 2011;20:834&#x2013;848. doi: 10.1002/pro.609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.609</ArticleId><ArticleId IdType="pmc">PMC3125868</ArticleId><ArticleId IdType="pubmed">21384452</ArticleId></ArticleIdList></Reference><Reference><Citation>Board P.G., Menon D. Glutathione transferases, regulators of cellular metabolism and physiology. Biochim. Biophys. Acta (BBA)-Gen. Subj. 2013;1830:3267&#x2013;3288. doi: 10.1016/j.bbagen.2012.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2012.11.019</ArticleId><ArticleId IdType="pubmed">23201197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex D.A.B., Dagamajalu S., Kandasamy R.K., Raju R., Prasad T.S. SARS-CoV-2 signaling pathway map: A functional landscape of molecular mechanisms in COVID-19. J. Cell Commun. Signal. 2021;15:601&#x2013;608. doi: 10.1007/s12079-021-00632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-021-00632-4</ArticleId><ArticleId IdType="pmc">PMC8237035</ArticleId><ArticleId IdType="pubmed">34181169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini D., Commodi J., Piroddi M., Incipini L., Sancineto L., Santi C., Galli F. Glutathione S-transferase pi expression regulates the Nrf2-dependent response to hormetic diselenides. Free Radic. Biol. Med. 2015;88:466&#x2013;480. doi: 10.1016/j.freeradbiomed.2015.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.06.039</ArticleId><ArticleId IdType="pubmed">26151571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Wong J., Henry B.M. Myalgia may not be associated with severity of coronavirus disease 2019 (COVID-19) World J. Emerg. Med. 2020;11:193. doi: 10.5847/wjem.j.1920-8642.2020.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7183921</ArticleId><ArticleId IdType="pubmed">32351656</ArticleId></ArticleIdList></Reference><Reference><Citation>Seixas M.L.G.A., Mitre L.P., Shams S., Lanzuolo G.B., Bartolomeo C.S., Silva E.A., Prado C.M., Ureshino R., Stilhano R.S. Unraveling Muscle Impairment Associated With COVID-19 and the Role of 3D Culture in Its Investigation. Front. Nutr. 2022;9:115. doi: 10.3389/fnut.2022.825629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.825629</ArticleId><ArticleId IdType="pmc">PMC8867096</ArticleId><ArticleId IdType="pubmed">35223956</ArticleId></ArticleIdList></Reference><Reference><Citation>Board P.G., Coggan M., Chelvanayagam G., Easteal S., Jermiin L.S., Schulte G.K., Danley D.E., Hoth L.R., Griffor M.C., Kamath A.V. Identification, characterization, and crystal structure of the Omega class glutathione transferases. J. Biol. Chem. 2000;275:24798&#x2013;24806. doi: 10.1074/jbc.M001706200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M001706200</ArticleId><ArticleId IdType="pubmed">10783391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes M.M., Hooftman A., Angiari S., Tummala P., Zaslona Z., Runtsch M.C., McGettrick A.F., Sutton C.E., Diskin C., Rooke M. Glutathione transferase omega-1 regulates NLRP3 inflammasome activation through NEK7 deglutathionylation. Cell Rep. 2019;29:151&#x2013;161. doi: 10.1016/j.celrep.2019.08.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.08.072</ArticleId><ArticleId IdType="pubmed">31577945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N., Di B., Xu L. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021;61:2&#x2013;15. doi: 10.1016/j.cytogfr.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8233448</ArticleId><ArticleId IdType="pubmed">34183243</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee C.M., Coll R.C. NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma. J. Leukoc. Biol. 2020;108:937&#x2013;952. doi: 10.1002/JLB.3MR0720-513R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3MR0720-513R</ArticleId><ArticleId IdType="pubmed">32745339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka-Kagawa T., Jinno H., Hasegawa T., Makino Y., Seko Y., Hanioka N., Ando M. Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn) Biochem. Biophys. Res. Commun. 2003;301:516&#x2013;520. doi: 10.1016/S0006-291X(02)03066-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)03066-8</ArticleId><ArticleId IdType="pubmed">12565892</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekoue D.N., He C., Diamond A.M., Bonini M.G. Manganese superoxide dismutase and glutathione peroxidase-1 contribute to the rise and fall of mitochondrial reactive oxygen species which drive oncogenesis. Biochim. Biophys. Acta (BBA) -Bioenerg. 2017;1858:628&#x2013;632. doi: 10.1016/j.bbabio.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC5689482</ArticleId><ArticleId IdType="pubmed">28087256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Lee E.-K., Kang D.H., Lee J., Hong S.H., Jeong W., Kang S.W. Glutathione peroxidase-1 regulates ASK1-dependent apoptosis via interaction with TRAF2 in RIPK3-negative cancer cells. Exp. Mol. Med. 2021;53:1080&#x2013;1091. doi: 10.1038/s12276-021-00642-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00642-7</ArticleId><ArticleId IdType="pmc">PMC8257591</ArticleId><ArticleId IdType="pubmed">34158609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu A.C.Y., Wang G., Reid A.T., Veerati P.C., Pathinayake P.S., Daly K., Mayall J.R., Hansbro P.M., Horvat J.C., Wang F. SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro. Biorxiv. 2020 doi: 10.1101/2020.09.30.317818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.30.317818</ArticleId></ArticleIdList></Reference><Reference><Citation>Notz Q., Herrmann J., Schlesinger T., Helmer P., Sudowe S., Sun Q., Hackler J., Roeder D., Lotz C., Meybohm P. Clinical significance of micronutrient supplementation in critically ill COVID-19 patients with severe ARDS. Nutrients. 2021;13:2113. doi: 10.3390/nu13062113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13062113</ArticleId><ArticleId IdType="pmc">PMC8235175</ArticleId><ArticleId IdType="pubmed">34203015</ArticleId></ArticleIdList></Reference><Reference><Citation>Blunt K., Jacobse J., Allaman M., Washington M., Goettel J., Wilson K., Williams C., Short S. GPX3 IS REQUIRED TO MEDIATE PROTECTIVE EFFECTS OF GPX1 LOSS IN COLITIS. Gastroenterology. 2022;162:S63. doi: 10.1053/j.gastro.2021.12.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.12.131</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghaddam A., Heller R.A., Sun Q., Seelig J., Cherkezov A., Seibert L., Hackler J., Seemann P., Diegmann J., Pilz M. Selenium deficiency is associated with mortality risk from COVID-19. Nutrients. 2020;12:2098. doi: 10.3390/nu12072098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12072098</ArticleId><ArticleId IdType="pmc">PMC7400921</ArticleId><ArticleId IdType="pubmed">32708526</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller R.A., Sun Q., Hackler J., Seelig J., Seibert L., Cherkezov A., Minich W.B., Seemann P., Diegmann J., Pilz M. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker. Redox Biol. 2021;38:101764. doi: 10.1016/j.redox.2020.101764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101764</ArticleId><ArticleId IdType="pmc">PMC7574778</ArticleId><ArticleId IdType="pubmed">33126054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihailovic S., Coric V., Radic T., Radojevic A.S., Matic M., Dragicevic D., Djokic M., Vasic V., Dzamic Z., Simic T. The Association of Polymorphisms in Nrf2 and Genes Involved in Redox Homeostasis in the Development and Progression of Clear Cell Renal Cell Carcinoma. Oxid. Med. Cell. Longev. 2021;2021:6617969. doi: 10.1155/2021/6617969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6617969</ArticleId><ArticleId IdType="pmc">PMC8068539</ArticleId><ArticleId IdType="pubmed">33953831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Peden D., Diaz-Sanchez D. Role of GSTM1 in resistance to lung inflammation. Free Radic. Biol. Med. 2012;53:721&#x2013;729. doi: 10.1016/j.freeradbiomed.2012.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.05.037</ArticleId><ArticleId IdType="pmc">PMC3418458</ArticleId><ArticleId IdType="pubmed">22683820</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi M.E.K., Karjalainen J., Liao R.G., Neale B.M., Daly M., Ganna A., Pathak G.A., Andrews S.J., Kanai M., Veerapen K. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>